tirzepatide cvot results In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx SURPASS-CVOT Published: Large Trial Confirms

The rapid clinical adoption of glucagon-like peptide-1 (GLP-1) receptor agonists and related anti-obesity pharmacotherapies represents one of the most consequential therapeutic shifts in metabolic medicine in decades

You may need a higher dosage The effects of tirzepatide are dose-dependent, meaning that people who take higher dosage strengths tend to lose more weight (for what its worth, they may experience more side effects, too)

Dosage: Adults: Take 1 tablet daily on an empty stomach, or as directed by your healthcare professional

SOAP2: an improved ultrafast tool for short read alignment

whether contrast-induced oxidative stress acts as a direct trigger, or if other intermediates (e.g., endoplasmic reticulum stress and mitochondrial dysfunction) are involved, requires definitive validation